Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did
postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer
Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from
the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed
Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research.
He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has
consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves
as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals.
His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune
system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics
for non-systemic applications.